Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics, a biotechnology company that develops therapies for multiple sclerosis, spinal cord injury and related nervous system disorders, has reported revenues of $63.62m for the third quarter ended 30 September 2010, compared to $15.21m for the same period in 2009.
Subscribe to our email newsletter
Acorda has posted a net income of $12.44m for the third quarter 2010, or $0.31 per diluted share, compared to net loss of $19.43m, or $0.51 loss per diluted share, for the comparable period in 2009.
Acorda’s operating income was $13.26m, compared to operating loss of $19m for the comparable period in 2009.
For the nine months ended 30 September 2010, the company has posted a revenue of $124.2m, compared to $40.23m for the year ago period.
Operating loss was $12.55m for the nine months ended 30 September 2010, compared to $59.22m for the year ago period.
Net loss was $15.44m, or $0.40 loss per diluted share, compared to $61.47m, or $1.63 loss per diluted share, for the year ago period.
Acorda president and CEO said that they continue to be pleased with the progress of the Ampyra launch and is gratified by the feedback from patients and physicians, and are proud that Ampyra is providing unique benefits to people with MS.